Cesar Rodriguez, MD

A complex case study in multiple myeloma management, exploring treatment sequencing options for a patient with a long history of disease and multiple lines of therapy.

Gain insight into strategies for monitoring for ICANS and CRS in myeloma treatment, including inpatient and outpatient administration, tocilizumab, dexamethasone, and impact on patient care.

Key opinion leaders share their insight on managing adverse events in myeloma treatment, including dose adjustments and prophylactic strategies to improve outcomes and patient quality of life.

Overview of challenges in managing adverse events associated with bispecific therapy in multiple myeloma, including dysgeusia, skin toxicity, and nail changes patients may experience.

Experts share how the availability of three new bispecific therapies has transformed myeloma patient care, offering a lifeline to those previously without treatment options and showcasing positive responses in various patient populations.

Insight into the latest updates on three approved bispecific therapies in the context of relapsed and refractory multiple myeloma, including teclistamab, talquetamab, and elranatamab, discussing response rates, administration, and side effects.

Dive into a compelling case study showcasing the effective use of talquetamab therapy in the management of relapsed multiple myeloma, discussing responses, side effects, and treatment outcomes.

Explore the potential in earlier use of novel therapy in multiple myeloma, including immunotherapy, bispecifics, and CAR-T therapies, with promising responses and potential paradigm shifts.

Join moderator Sagar Lonial, MD, FACP, and a panel of experts as they discuss recent updates in the management of relapsed and refractory multiple myeloma, exploring impact on clinical practice.

Before closing out their discussion with key takeaways, expert panelists highlight novel non-BCMA targeting bispecifics in the setting of multiple myeloma.

Panelists reflect on the evolving landscape of BCMA targeting bispecifics and how additional agents will impact the management of multiple myeloma.

Key opinion leaders consider when it is appropriate to utilize bispecific dose holds or reductions when treating patients with multiple myeloma.

Focused discussion on how patients receiving bispecific therapy for multiple myeloma are transitioned into and managed within the community setting.

Expert panelists share insight on transitioning patients on bispecific therapy from an academic or specialty center to the community setting.

Long-term considerations for the detection and treatment of CRS and other adverse events when managing patients with multiple myeloma.

Expert perspectives on ensuring the early detection and treatment of CRS and other adverse events when initiating bispecific therapy in patients with multiple myeloma.

Key opinion leaders in multiple myeloma management address barriers inherent in the selection and use of bispecifics.

Experts Scott A. Soefje, PharmD, and Kirollos S. Hanna, PharmD, share their perspectives on initial steps in initiating bispecific therapy for patients with multiple myeloma.

Frances A. Bell, NP, leads a conversation on key steps taken leading up to the initial administering of bispecific therapy in patients with multiple myeloma.

Shared insight on the role bispecifics will play in multiple myeloma management as other novel agents and clinical trials continue to enter the landscape.

Panelists provide a broad-view perspective on established treatment pathways with bispecifics in multiple myeloma and the most prevalent challenges tied to this class of therapy.

Moderator Cesar Rodriguez, MD, spearheads a discussion on the current state of the multiple myeloma treatment paradigm with a focus on bispecifics in the multiply relapsed setting.

Closing out the panel discussion, experts review the management of bispecific-related toxicities and share their final thoughts on treating patients with multiple myeloma.

Expert oncologists discuss Belantamab mafodotin, its recent withdrawal from the U.S. market, and the clinical implications of the DREAMM trials for patients with R/R multiple myeloma.

Shared perspective on the potential role of ADCs, CAR T-cell therapy, and other agents in combination treatment with bispecifics for patients with multiple myeloma.

Focusing their discussion on clinical data in R/R multiple myeloma studies, panelists highlight current and emerging bispecific antibodies for treating patients that have progressed after multiple lines of therapy.

Expert panelists discuss treatment approaches for patient with multiple myeloma that have progressed and are relapsed and/or refractory (R/R).

Experts offer final thoughts on the treatment of newly diagnosed MM for patients that are transplant-ineligible.

Oncology expert panelists review patient subgroup analyses for MAIA and SWOG0777 studies, investigating treatments for transplant-ineligible patients with newly diagnosed multiple myeloma.

Expert panelists review clinical data from studies investigating treatment regimens for patients with NDMM that are transplant-ineligible.